SOURCE: bioRASI

October 16, 2006 12:33 ET

bioRASI Names George K. Gessner Vice President of Business Development

bioRASI Brings Industry Veteran On-Board to Lead the Expansion of Its North American Business Development Efforts

MIAMI, FL -- (MARKET WIRE) -- October 16, 2006 -- Global CRO bioRASI, a strategic initiative of the 250,000 person-strong Russian Academy of Sciences, announced today that George K. Gessner has joined the company as Vice President of Business Development. Due to its increased focus on North American markets, bioRASI has significantly expanded its US business development infrastructure and named Mr. George K. Gessner to lead these efforts.

"We are extremely pleased to bring a person of George's caliber to head our business development efforts in North America. In over three decades of helping shape the drug development industry, he has covered everything from discovery to licensing & commercialization to business development," said Dr. Boris Reznik, Chairman of bioRASI. "In every area George has proved himself a very strong leader; likeable, knowledgeable, and well trusted by the industry."

Prior to joining bioRASI, George K. Gessner served as Vice President of Business Development for SFBC International, one of the largest North American CROs, as well as was the founder and President of Research Resources International (RRI), another successful CRO. Previously, he has held senior management positions with major drug developers including Johnson & Johnson, Merck Inc. and William H. Rorer.

"I am very excited about joining the bioRASI Team, some of the most dedicated, knowledgeable and accomplished professionals in the industry," said Mr. Gessner. "It is extremely rewarding to be in a position to help optimize the drug development efforts of my long-term industry colleagues by leveraging the powerful world-wide capabilities of the Strategic Initiative of the Russian Academy of Sciences," he continued.

About bioRASI:

bioRASI is a full service global CRO uniquely positioned to provide Optimized Pipeline Development™ to biotechnology and pharmaceutical companies. A strategic initiative of the 250,000 person-strong Russian Academy of Sciences, bioRASI conducts research throughout the Americas, Europe, and Asia. bioRASI is experienced in biologicals, medical devices, and small drugs across a wide range of indications, maintaining equal balance between Pilot, Phase I/BE, and Phase II/IV studies. Applying this comprehensive set of capabilities, bioRASI is able to significantly expand and accelerate the development of its clients' therapeutics pipelines. bioRASI is co-headquartered in Miami, FL and Moscow, R.F., and has regional offices across the globe.

Contact Information